Add BrightSurf on Google Email

Scientists create a type of catalog, the ‘colocatome,’ of non-cancerous cells’ influence on cancer

Researchers develop a 'colocatome' to study the interactions between cancer cells and their surrounding non-cancerous cells, revealing how these interactions impact tumor growth and treatment resistance. The study aims to provide insights into universal rules of tumor behavior and guide the design of more effective treatments.

SourceStanford Medicine·JournalNature Communications·TypeImaging analysis·DateMar 11, 2025

Study reveals hope for immunotherapy as prostate cancer treatment

Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...

SourceUniversity of Arizona Health Sciences·JournalCancer Immunology Research·TypeExperimental study·DateMar 4, 2025

Chinese Medical Journal article reveals the anticancer potential of poly ADP-ribose polymerase inhibitors

PARP inhibitors have been found to be effective in treating cancers with BRCA1/2 mutations by blocking DNA repair pathways. The combination of PARPis with chemotherapeutic drugs can also improve treatment efficacy, increasing DNA damage and blocking repair processes.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateMar 4, 2025

What makes cancer cells weak

A study by Andreas Koeberle and colleagues reveals that certain natural substances can increase polyunsaturated fatty acids in cancer cell membranes, making them susceptible to ferroptosis, a type of cell death. This discovery creates new avenues for treating therapy-resistant tumours.

SourceUniversity of Graz·JournalNature Communications·TypeExperimental study·DateFeb 25, 2025

Innovative dual-target drug may lead to new investigational approach for breast cancer patients

Researchers at University of Melbourne and Pfizer discover new insights into a dual-target drug that may supercharge cancer-fighting immune cells, potentially leading to improved outcomes for breast cancer patients. The study found that this approach can enhance anti-tumor immunity by intratumoral CD8+ T cells.

SourceUniversity of Melbourne·JournalClinical & Translational Immunology·TypeExperimental study·DateFeb 11, 2025

KAIST discovers molecular switch that reverses cancerous transformation at the critical moment of transition​

Researchers at KAIST have discovered a molecular switch that can induce cancer reversal by capturing the moment of critical transition before normal cells become irreversibly cancerous. The technology uses single-cell RNA sequencing data and computer simulation analysis to identify the molecular switch.

SourceThe Korea Advanced Institute of Science and Technology (KAIST)·JournalAdvanced Science·TypeMeta-analysis·DateFeb 6, 2025

Damon Runyon Cancer Research Foundation awards $3.2 million to innovative early-career scientists

The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.

NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.

SourceNational University of Singapore·JournalAdvanced Functional Materials·TypeExperimental study·DateJan 27, 2025

Research using non-toxic bacteria to fight high-mortality cancers prepares for clinical trials

Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.

SourceUniversity of Massachusetts Amherst·JournalMolecular Therapy·TypeRandomized controlled/clinical trial·DateJan 16, 2025

Trastuzumab emtansine improves long-term survival in HER2 breast cancer

The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.

SourceUniversity of Pittsburgh·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 15, 2025

Researchers shed light on how to predict which skin cancer patients are most likely to respond to immunotherapy

A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.

SourceUniversity of Bath·JournalJCO Oncology Advances·TypeExperimental study·DateJan 8, 2025

Researchers reveal why the lung is a frequent site of cancer metastasis

The study found that high levels of aspartate in the lungs are associated with aggressive lung metastases, triggered by an alternative translation program driven by aspartate signaling. This discovery suggests a common feature of cancer cells growing in the lung and provides a potential target for new therapeutic interventions.

SourceVlaams Instituut voor Biotechnologie·JournalNature·TypeExperimental study·DateJan 1, 2025

Controlling cancer cells’ gluttony for glutamine

Researchers at Sanford Burnham Prebys found that pancreatic cancer cells rely on a specific nutrient, glutamine, to fuel their unchecked growth. The study identified two enzymes, aPKC zeta and iota, that play a regulatory role in the process of macropinocytosis, allowing cancer cells to scavenge alternative resources.

SourceSanford Burnham Prebys·JournalNature Communications·TypeExperimental study·DateDec 5, 2024

Gluing treatment to cancer

Combining PVA with a boron-containing compound improved the effects of radiation therapy for cancer, making it more selective of tumor cells and prolonging drug retention. This breakthrough could lead to more effective treatment options for challenging cancers.

SourceUniversity of Tokyo·JournalJournal of Controlled Release·TypeExperimental study·DateDec 3, 2024

Gold beats platinum for chemo drugs in new lab study

A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.

SourceRMIT University·JournalEuropean Journal of Medicinal Chemistry·TypeExperimental study·DateNov 26, 2024

Moffitt study shows how cancer cell death may harm the immune system and promote tumor growth

Researchers found that a type of cancer cell death called necroptosis can release a molecule called interleukin-1α, weakening the immune response and allowing tumors to grow faster. By blocking this molecule, cancer treatments like chemotherapy and immunotherapy may become more effective.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalCancer Cell·TypeObservational study·DateNov 26, 2024

Cancers grow uniformly throughout their mass

Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.

New microfluidic device reveals how the shape of a tumour can predict a cancer’s aggressiveness

Researchers at University of Toronto have developed a new microfluidic platform, ReSCUE, that allows for unprecedented control and manipulation of tumor shapes. This enables the formation, release, and transfer of patient-derived tumoroids, providing insights into how tumor shape predicts cancer cell behavior and aggressiveness.

Genetic variation enhances cancer drug sensitivity

A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.

SourceUppsala University·JournalEBioMedicine·TypeExperimental study·DateNov 14, 2024